沛嘉醫療-B(09996.HK):加奇醫療與暖陽醫療訂立獨家分銷協議
格隆匯8月28日丨沛嘉醫療-B(09996.HK)發佈公吿,2024年8月16日,公司全資附屬公司Achieva Medical Limited(“加奇醫療”)與江蘇暖陽醫療器械有限公司(“暖陽醫療”)訂立獨家分銷協議。根據該協議,暖陽醫療將委任加奇醫療為大中華區的獨家分銷商,負責YonFlow®血流導向裝置的銷售和分銷,自該協議日期起為期八年。
YonFlow®血流導向裝置是暖陽醫療的核心產品,也是全球首款完全釋放後可回收的血流導向支架系統。2023年1月,該產品通過創新醫療器械審評,並獲國家藥品監督管理局(“國家藥監局”)創新醫療器械特別審批程序受理。於本公吿日期,該產品的註冊批准申請已提交至國家藥監局,預計將於近期獲得批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.